Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GalenicaXSWX:GALE -0.24%80 Days Sales Outstanding is 46.58 as of Jun. 2026, which is 10% above its 10-year median of 42.40. GuruFocus rates XSWX:GALE with a GF Score™ of 80/100 and a GF Value™ of CHF87.78 (Fairly Valued). The stock has 1 warning sign investors should review. Among 117 Medical Distribution companies, Galenica ranks better than 79.49% on this metric.
Galenica's average Accounts Receivable for the
six
months ended in Jun. 2026 was CHF545 Mil. Galenica's Revenue for the
six
months ended in Jun. 2026 was CHF2,136 Mil.
Hence, Galenica's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 46.58.
The historical rank and industry rank for Galenica's Days Sales Outstanding or its related term are showing as below:
XSWX:GALE'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.42 Med: 42.4 Max: 48.76
Current: 48.76
During the past 13 years, Galenica's highest Days Sales Outstanding was 48.76. The lowest was 39.42. And the median was 42.40.
XSWX:GALE's Days Sales Outstanding is ranked better than 79.49% of 117
companies
in the Medical Distribution industry
Industry Median: 74.42
vs XSWX:GALE: 48.76
Galenica's Days Sales Outstanding
declined
from Jun. 2025 (49.55) to Jun. 2026 (46.58).
Galenica (XSWX:GALE) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Galenica Days Sales Outstanding Related Terms
Galenica Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Galenica's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALE vs MCK, COR, CAH: Days Sales Outstanding Comparison
For the Medical Distribution subindustry, Galenica's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galenica Days Sales Outstanding vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Galenica's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Galenica's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galenica (XSWX:GALE) has a Days Sales Outstanding of 46.58 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Galenica and its competitors. This is 10% above median its historical median of 42.40. Over the past decade, Galenica's Days Sales Outstanding has ranged from 39.42 to 48.76. According to the industry distribution chart, Galenica ranks #24 out of 117 companies in the Medical Distribution industry, placing it in the top 20.5%.
Is Galenica's Days Sales Outstanding too high?
Galenica's current Days Sales Outstanding of 46.58 is 10% above median its 10-year median of 42.40. Over the past 10 years, this metric has ranged from a low of 39.42 to a high of 48.76. The Medical Distribution industry median Days Sales Outstanding is 74.42. Galenica's value of 46.58 is 37.4% below this industry median. Based on the distribution chart, Galenica ranks #24 out of 117 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Galenica has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Galenica's Days Sales Outstanding compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Galenica ranks #24 out of 117 companies for Days Sales Outstanding. This places Galenica in the top 21% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 74.42. Galenica's value of 46.58 is 37.4% below this benchmark. Historically, Galenica's own Days Sales Outstanding has ranged from 39.42 to 48.76 over the past decade. While the company's 10-year median is 42.40 vs. the industry median of 74.42, Galenica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Distribution company?
The median Days Sales Outstanding among Medical Distribution companies is 74.42, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galenica's current Days Sales Outstanding of 46.58 is 37.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Galenica and its competitors. For the Medical Distribution industry, the median Days Sales Outstanding is 74.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galenica's current Days Sales Outstanding is 46.58, which is 10% above median its own 10-year median of 42.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galenica stock overvalued right now?
Based on GuruFocus' analysis, Galenica (XSWX:GALE) is currently considered Fairly Valued. The stock's GF Value™ is CHF87.78, compared to a current price of CHF82.90 — trading 5.6% below its estimated fair value. The current Days Sales Outstanding is 46.58, which is 10% above median its 10-year median of 42.40 and 37.4% below the Medical Distribution industry median of 74.42. Galenica's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Galenica (XSWX:GALE), the current Days Sales Outstanding is 46.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Galenica (XSWX:GALE) Overvalued in 2026?
Based on GuruFocus' analysis, Galenica stock appears to be undervalued.
The current stock price of CHF82.90 is trading 5.6% below its estimated GF Value™ of CHF87.78.
GuruFocus considers Galenica to be Fairly Valued.
Key valuation signals for XSWX:GALE:
Days Sales Outstanding: 46.58 (10% above median its 10-year median of 42.40)
GF Value™: CHF87.78 vs. price of CHF82.90 (5.6% below fair value)
Industry Position: 37.4% below the Medical Distribution median (#24 of 117)
No single metric tells the full story. See the XSWX:GALE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Galenica Ltd is an integrated healthcare service provider in Switzerland. The business is operated from two segments Products & Care and Logistics & IT. The Products & Care segment comprises the Retail business area with offerings for patients and end customers and the Professionals business area with offerings for business customers and partners in the healthcare sector. The Logistics & IT segment comprises the two sectors Wholesale and Logistics & IT Services. These provide services for all those involved in the healthcare sector - pharmacies, drugstores, doctors, hospitals and care homes, partners, and suppliers. Geographically, it operates in Switzerland and Other Countries.
80GF Score
Get the complete analysis for XSWX:GALE
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALE has been successfully added to your 
